MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Jaguar Health Revenue 2011-2026 | JAGX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Jaguar Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.7 M | 9.76 M | - | 4.34 M | 9.38 M | 5.78 M | 4.42 M | 4.36 M | 142 K | 258 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 142 K | 5.57 M |
Quarterly Revenue Jaguar Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.08 M | 2.98 M | 2.21 M | 3.11 M | 2.72 M | 2.35 M | 2.81 M | - | - | - | - | - | - | - | - | - | - | - | 2.77 M | 3.17 M | 869 K | - | 973 K | 1.71 M | 1.59 M | - | 1.13 M | 884 K | 804 K | - | 1.1 M | 897 K | 822 K | - | 50.4 K | 24.1 K | 38.1 K | - | - | 63.1 K | 62.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.17 M | 24.1 K | 1.51 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Takeda Pharmaceutical Company Limited
TAK
|
3.2 T | $ 18.06 | - | $ 28.2 B |  Japan |
 |
Amphastar Pharmaceuticals
AMPH
|
720 M | $ 19.44 | -0.46 % | $ 909 M |  USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
54 K | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M |  Israel |
 |
Protara Therapeutics
TARA
|
2.95 M | $ 5.03 | -3.08 % | $ 215 M | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
451 M | $ 67.0 | -0.3 % | $ 2.8 B | USA |
 |
bluebird bio
BLUE
|
29.5 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Theravance Biopharma
TBPH
|
45.9 M | $ 14.9 | -1.91 % | $ 750 M |  Cayman-islands |
 |
Avid Bioservices
CDMO
|
140 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
242 K | $ 1.2 | -6.97 % | $ 306 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
5.34 B | - | 0.49 % | $ 251 B | Cayman-islands |
 |
Bio-Techne Corporation
TECH
|
1.22 B | $ 51.31 | -2.65 % | $ 8.08 B | USA |
 |
Tenax Therapeutics
TENX
|
49.3 K | $ 14.64 | -2.2 % | $ 574 M | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
21 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
32.2 M | - | - | $ 3.74 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
1.5 B | $ 28.76 | -3.43 % | $ 32.9 B | Israel |
 |
Enochian Biosciences
ENOB
|
42.8 K | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
41.1 M | $ 2.03 | -1.46 % | $ 116 M | USA |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 23.81 | 1.51 % | $ 641 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
3.51 M | $ 46.38 | -2.45 % | $ 4.17 B |  Schweiz |